ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TSHA vs JNJ // FORWARD P/E MULTIPLE

Taysha Gene Therapies Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TSHA 2 — JNJ 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TSHA VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TSHA JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -6.82% 2.97% -9.79 JNJ /fcf-yield <GO>
Operating Margin -60.00% 34.70% -94.70 JNJ /operating-margins <GO>
Net Profit Margin -60.00% 28.50% -88.50 JNJ /net-margins <GO>
Revenue Growth (YoY) 17.30% 6.00% +11.30 TSHA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.67 5.59 +0.08 TSHA /balance-sheet <GO>
Piotroski F-Score Quality 4/9 8/9 -4.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.8 62.1 -15.30 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.38B $662.49B -$661.12B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TSHA REV JNJ REV TSHA GROSS % JNJ GROSS % TSHA FCF JNJ FCF
FY 2025 $9.8M $94.19B — 67.9% -$93.8M $19.70B
FY 2024 $8.3M $88.82B — 69.1% -$81.6M $19.84B
FY 2023 $15.5M $85.16B — — -$73.0M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TSHA // BETA —
JNJ // BETA 1.08